Amaç: Kardiyovasküler hastalıklar, kronik böbrek hastalığı (KBH) olanlarda önde gelen ölüm sebebidir. KBH' nın klopidogrel cevabı üzerine olan etkisi hakkında çeliş-kili kanıtlar vardır. Bu çalışmada, akut koroner sendromlu kronik böbrek hastalarında klopidogrel yanıtını değerlen-dirmeyi amaçladık. Sonuç: Klopidogrele trombosit yanıtı; eGFH < 60 ml/ dak/1.73 m2 ve eGFH>60 ml/dak/1.73 m2 olan hastalar arasında değişmiyor.
INTRODUCTION
Clopidogrel is a thienopyridine that irreversibly inhibits platelet adenosine diphosphate P2Y12 receptor, which is a key signaling pathway of the platelet activation. Clopidogrel is widely used in patients with coronary artery disease. Dual antiplatelet treatment is the standard therapy for patients after acute coronary syndromes (ACS) and undergoing percutaneous coronary interventions (PCI). Guidelines recommend 1 year dual antiplatelet treatment in patients with ACS [1] .
Interindividual variability of response to clopidogrel therapy has been demonstrated in some studies [2] . The clinical importance of this situation has been demonstrated in different clinical conditions such as ACS and after PCI [3] [4] [5] . Although clopidogrel resistance is used in clinical practice; in fact it is a low responsiveness to clopidogrel. It is a multifactorial phenomenon. Variability of platelet response to clopidogrel is likely to develop as a result of a decreased bioavailability of the active metabolite, due to genetic variation or concomitant drug treatment [2] .
Cardiovascular diseases are the leading cause of death in patients with chronic kidney disease (CKD). Patients with all stages of CKD experience higher rates of atherothrombotic disease manifestations than the general population [6] [7] [8] . This underlies the importance of antithrombotic therapy in these patients. There is conflicting evidence about effect of CKD on clopidogrel responsiveness. Some studies demonstrated high rates of clopidogrel low responsiveness (CLR) in CKD patients [9, 10] whereas someother did not showed any relation [11] .
The aim of our study was to evaluate the clopidogrel responsiveness in CKD patients with ACS.
METHODS
This study was approved by the local ethics committee, and all participants gave written informed consent before participating.
Estimated glomerular filtration rate (eGFR) of 312 consecutive patients hospitalized with ACS was calculated by using the Modification of Diet in Renal Disease Study Formula [12] . 46 of these patients with normal renal function or mild CKD and 55 with moderate to severe CKD, total 101 patients were included in the study. We classified the 101 patients into two study groups according to their eGFR values. Group 1 included 55 patients with moderate to severe CKD (eGFR< 60 ml/min/1.73 m2) and group 2 included 46 patients with mild CKD or normal renal function (eGFR> 60 ml/min/1.73 m2). Aspirin and clopidogrel responsiveness were assessed after 7 days of regular 100 mg acetyl salicylic acid (ASA) and clopidogrel 75 mg once a day prescription. The discharged patients during this period were called for the test and their drug compliance were determined by patient interviews.
Patients taking an antiplatelet therapy other than ASA and clopidogrel (ticlopidine, dipyridamole, nonsteroidal anti-inflammatory drugs, pentoxyphillin, cilostazol), previous treatment with glycoprotein IIb/IIIa inhibitors within 10 days, active malignancy, hemorrhagic diathesis, thrombolytic treatment within the last month, liver disease, platelet counts <100,000/ml, and noncompliant with medical therapy were not included in the study.
Information on diabetes, hypertension, hyperlipidemia, smoking, and medication history of the patients were recorded. Fasting blood samples were obtained to determine creatinine, blood urea nitrogen (BUN), uric acid, blood glucose, lipid profile, hemoglobin, mean platelet volume (MPV), leucocyte, and platelet count. We used the multiplate test (Dynabyte Medical, Munich, Germany) to determine clopidogrel responsiveness.
Assessment of clopidogrel responsiveness
Whole blood was obtained via standard venipuncture at an antecubital vein. Blood was collected in tubes containing the anticoagulant hirudin. The ADP-induced platelet aggregation in whole blood was assessed with multiple electrode aggregometry using an impedance aggregometer called Multiplate analyzer within two hours of sampling after two to four hours of drug ingestion. Details of this method have been reported previously [13] . In brief, after 1:1 dilution of whole blood with 0.9% NaCl solution and stirring for 3 min in the test cuvettes at 37°C, 6.4 µmol/l ADP was added. Platelet aggregation was continuously recorded for 5 min. Impedance with Multipl electrode aggregometry is transformed to arbitrary aggregation units (AU) that are plotted against time (AU*min). Aggregation mea-sured is quantified as AU and area under the curve of arbitrary units (AU*min) and values over 470 AU*min were accepted as CLR.
Assessment of aspirin responsiveness
Whole blood aggregation was performed with the multiplate analyzer, an impedance aggregometer that is based on the principle that activated platelets expose receptors on their surface that allow them to attach to artificial surfaces. After two to four hours of aspirin ingestion, whole blood samples were collected in test tubes containing hirudin (25 mcg/ml) as anticoagulant. Arachidonic acid was used as the aggregation agonist, and all samples were analyzed within 2 hours of collection. The aggregation measured with this device is quantified as area under the curve, aggregation degree, and aggregation velocity. Platelet aggregation results were presented as aggregation unit (AU)*min, and values over 500 AU*min were accepted as aspirin resistance (AR) [14] .
Statistical analysis
Continuous variables were presented as mean ± standard deviation. Categorical variables were presented as frequencies and percentages. The unpaired Student's t-test for continuous variables and χ2-test for categorical variables was performed to compare the study groups in relation to eGFR levels and patients groups with and without CLR. Correlations between the multiplate test results and CLR status with other parameters were analyzed using Spearman's or Pearson's correlation analysis. Multivariate associations of the multiplate test results were determined by using multiple stepwise linear regression analysis with parameters having significant correlations in the univariate analysis. For the determination of the influential factors on CLR, multivariate logistic regression analysis was also performed on variables with a p value of <0.05 derived from the univariate analysis. The receiver-operating characteristics (ROC) curve was used to test the predictive accuracy of eGFR with respect to the presence of CLR based on Multiplate test results. Significant prediction was accepted when the area under the ROC curve was significantly different from 0.5. p<0.05 was accepted as statistically significant. All analyses were performed using SPSS 15.0 statistical software. GFR were not correlated with CLR status (r=-0.127, p=0.207) and also showed no significant discriminatory capacity between clopidogrel low responder and clopidogrel sensitive patients, having an area under the ROC curve of 0.577 (CI 0.458-0.695), p=0.205 (Figure 2) . 
RESULTS

The
DISCUSSION
In the present study, we did not observe any significant differences of clopidogrel responsiveness between the patients with normal renal function or mild CKD (eGFR > 60 ml/min/1.73 m 2 ) and moderate to severe CKD and not on chronic hemodialysis treatment. CLR was independently related to only Multiplate test results of aspirin responsiveness and hemoglobin. eGFR was not related to CLR and could not predict it.
In large randomized controlled trials, CKD has been linked with a lower efficacy of clopidogrel [15] and there are papers with different results about effects of CKD on clopidogrel responsiveness. Park et al [10) reported that platelet responsiveness to clopidogrel decreased more in patients with CKD than in those with normal renal function and this decreased response was not improved by increased dosage. They included severe CKD patients (patients had CKD for > 6 months and with a serum creatinine concentration > 3 mg/dl) in their CKD group and the sample size of the study was smaller. Their study included both patients with stable angina pectoris and unstable angina pectoris in contrast to our study group with ACS. Clopidogrel responsiveness was also determined by VerifyNow, not Multiplate method. Angiolillo et al showed impaired renal function was associated with reduced clopidogrel-induced antiplatelet effects in diabetic patients with coronary artery disease taking maintenance aspirin and clopidogrel therapy. Their study group was only diabetics and clopidogrel responsiveness was assessed by light transmittance aggregometry method.
Like our study results; Cuiset et al also did not find any significant effect of CKD on clopidogrel responsiveness assessed by PRI VASP, neither for acute response, nor for chronic response with high dose [11] in the patients with ACS .
The mechanisms leading to variability in clopidogrel responsiveness are not fully understood, but likely to be multifactorial. It is caused by genetic and nongenetic causes. Increased baseline platelet reactivity; commonly observed in some clinical scenarios such as ACS, diabetes mellitus and increased body mass index may lead to decreased clopidogrel responsiveness. [16] [17] [18] [19] . Differences in individual absorption of clopidogrel and levels of its active metabolite may also lead to clopidogrel response variability [20] . Also drugs that are substrates or inhibit the CYP isoenzyme 3A4 can lead to reduced antiplatelet effects [21] .
Cardiovascular diseases are the leading cause of death in patients with CKD. These patients are at increased risk for both thrombosis and hemorrhage. Morel et al reported low platelet response to clopidogrel was associated with worse outcomes after PCI in patients with CKD [22] . Also in their study degree of P2Y12 inhibition by clopidogrel was not significantly different in the CKD and non-CKD groups. Htun et al also demonstrated low response to clopidogrel was an additional risk factor for the poorer post-PCI outcomes in patients with moderate to severe CKD patients [23] . So it is important to highlight if aspirin and clopidogrel responsiveness are lower in CKD patients and to decide the management of this situation without increasing hemorrhagic complications. As the patients with CKD also prone to hemorrhagiac complications it is important to avoid high dose of antithrombotic treatments without any evidence.
We did not include patients with end-stage renal disease and on chronic hemodialysis. This is the limitation of our study and large studies with all stages of CKD patients including hemodialysis patients with both predialysis and postdialysis tests are needed to clear the relation between CKD and antiplatelet responsiveness.
In conclusion, Platelet response to clopidogrel does not differ between patients with mild CKD or normal renal function and patients with moderate to severe CKD.
